Trial Profile
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MYSTIC
- Sponsors AstraZeneca; AstraZeneca AB
- 16 Jan 2024 Planned End Date changed from 29 Jun 2023 to 31 Dec 2024.
- 19 Apr 2023 Results assessing the impact of clonal hematopoietic on molecular response measurement, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 04 Jan 2023 Planned End Date changed from 30 Dec 2022 to 29 Jun 2023.